Kefah Mokbel, Professor of Medicine (Honorary) at Cardiff University School of Medicine, shared on LinkedIn:
“Carboplatin in early TNBC: can we better identify who benefits?
An updated systematic review and meta-analysis by Wu and colleagues in Breast Cancer Research and Treatment assessed the incremental benefit of adding carboplatin to otherwise substantially comparable chemotherapy regimens.
Across seven randomized contrasts involving 2,627 participants contributing disease-control evidence:
- Disease control improved: HR 0.779 (95% CI 0.671–0.904).
- The odds of pathological complete response increased: OR 2.038 (95% CI 1.653–2.512).
- An overall survival benefit was not established: HR 0.810 (95% CI 0.627–1.046).
These findings support carboplatin’s benefit at a population level. They do not tell us that every patient benefits – or by how much.
For me, the next question is patient selection. Can we identify those with the greatest absolute benefit, and those for whom additional toxicity may outweigh a small incremental gain?
A biomarker associated with chemotherapy response is not necessarily predictive of the added benefit of carboplatin. In GeparSixto, genomic HRD was associated with response but did not predict carboplatin-specific benefit. Functional assays such as RAD51 have shown promising exploratory results, but need further validation before guiding treatment omission.
What evidence would we need to move from population-level benefit to biomarker-guided selection – particularly within contemporary chemo-immunotherapy regimens?
You can also read: Neoadjuvant Carboplatin Improves Event-Free Survival in Early TNBC: Pooled Analysis of Three Randomized Trials Strengthens the Evidence
